(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 15.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Immunocore Holdings's revenue in 2025 is $333,581,000.On average, 6 Wall Street analysts forecast IMCR's revenue for 2025 to be $19,752,508,096, with the lowest IMCR revenue forecast at $19,148,951,284, and the highest IMCR revenue forecast at $20,171,305,694. On average, 6 Wall Street analysts forecast IMCR's revenue for 2026 to be $21,932,696,960, with the lowest IMCR revenue forecast at $19,986,245,078, and the highest IMCR revenue forecast at $23,550,520,571.
In 2027, IMCR is forecast to generate $25,933,954,618 in revenue, with the lowest revenue forecast at $23,424,936,549 and the highest revenue forecast at $29,773,460,054.